Akatinol Memantine, 20 mg 28 pcs

How to take, the dosage

Internal, with meals. Dosing regimen is set individually. It is recommended to start treatment by prescribing the lowest effective dose.

In adults with dementia, during the 1st week of therapy – in a dose of 5 mg/day, the 2nd week – in a dose of 10 mg/day, the 3rd week – in a dose of 15-20 mg/day. If necessary, further weekly dose increase by 10 mg to reach a daily dose of 30 mg.

The optimal dose is reached gradually by increasing the dose each week.

Interaction

Concomitant use with L-dopa drugs, dopamine agonists, anticholinergic agents may increase the effect of the latter.

Concomitant use with barbiturates, neuroleptics may decrease their effect.

Concomitant use may change (increase or decrease) the effect of dantrolene or baclofen; therefore the doses of the drugs should be adjusted individually. Concomitant administration with amantadine, ketamine and dexamethorphan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, quinine and nicotine when concomitantly administered with memantine. There may be decreased levels of hydrochlorothiazide when concomitantly taken with memantine.

Special Instructions

With caution is prescribed in epilepsy, patients with thyrotoxicosis. The optimal dose is reached gradually, with weekly increases.

In patients with Alzheimer’s disease at the stage of moderate to severe dementia the ability to drive vehicles and operate complex mechanisms is usually impaired.

In addition, memantine may cause changes in reaction speed, so patients treated as outpatients should use extra caution when driving or operating machinery.

Contraindications

• Individual hypersensitivity to the drug Akatinol Memantine;
• explicit renal dysfunction;
• pregnancy;
• breastfeeding;
• children under 18 years of age (due to insufficient data).

With caution:

• thyrotoxicosis;
• epilepsy;
• convulsions (including.
• myocardial infarction
• heart failure.

Side effects

Adverse reactions are classified according to clinical manifestations (according to the involvement of certain organ systems) and by frequency of occurrence:

In the body as a whole – general adverse reactions

Often Headache

Rarely Fatigue

Infections Rarely Fungal infections

Mental disorders Frequent Sleepiness

p> Rarely Confusion

Rarely Hallucinations

Frequency not determined

Psychotic reactions

Cardiovascular disorders

Rarely Hypertension

p> Rarely Venous thrombosis/thromboembolism

Gastrointestinal disorders Frequently Constipation

Rarely Nausea, vomiting

Frequent Not Established Pancreatitis

Disorders of the central and peripheral nervous systembr>

Often Dizziness

Rarely Impaired gait

Very rarely Seizures

/p>

Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

There have been anecdotal reports of these adverse reactions when the drug is used in clinical practice (data obtained after the drug was commercially available).

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

Contraindicated.

Similarities

Noogeron, Maruksa, Memantal, Memaneirin, Memantine